Vor Biopharma Inc.
VOR
$16.10
$1.177.84%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 166.54% | 181.23% | 115.29% | -66.76% | -17.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.61% | 14.85% | 2.18% | 738.82% | 2.99% |
| Operating Income | -5.61% | -14.85% | -2.18% | -738.82% | -2.99% |
| Income Before Tax | -575.94% | 5,709.72% | -2,848.89% | -5,552.75% | -5.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -575.94% | 5,709.72% | -2,848.89% | -5,552.75% | -5.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -575.94% | 5,709.72% | -2,848.89% | -5,552.75% | -5.46% |
| EBIT | -5.61% | -14.85% | -2.18% | -738.82% | -2.99% |
| EBITDA | -8.21% | -18.04% | -5.32% | -757.46% | -3.45% |
| EPS Basic | 1.92% | 1,067.73% | -1,410.89% | -2,981.92% | 42.52% |
| Normalized Basic EPS | 1.92% | 1,065.40% | -1,412.82% | -2,921.77% | 42.52% |
| EPS Diluted | 1.92% | 1,067.73% | -1,410.89% | -2,981.92% | 42.52% |
| Normalized Diluted EPS | 1.92% | 1,065.40% | -1,412.82% | -2,921.77% | 42.52% |
| Average Basic Shares Outstanding | 589.15% | 479.67% | 95.17% | 83.41% | 83.48% |
| Average Diluted Shares Outstanding | 589.15% | 479.67% | 95.17% | 83.41% | 83.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |